Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Sell
1
EDIT Quote, Financials, Valuation and Earnings
Last price:
$1.30
Seasonality move
:
-5.52%
Day range:
$1.26 - $1.33
52-week range:
$1.12 - $7.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.34x
P/B ratio:
0.81x
Volume:
2.9M
Avg. volume:
5.6M
1-year change:
-83.27%
Market cap:
$108.7M
Revenue:
$32.3M
EPS (TTM):
-$2.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$1.3M | -$0.42 | -23.05% | -22.53% | $3.75 |
|
ADMA
ADMA Biologics
|
$121.3M | $0.18 | 42.17% | 75% | $25.27 |
|
EYPT
EyePoint Pharmaceuticals
|
$6.8M | -$0.72 | -24.38% | -22.59% | $33.00 |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
PTCT
PTC Therapeutics
|
$166.2M | -$1.24 | 119.66% | -34.58% | $64.93 |
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
$1.31 | $3.75 | $108.7M | -- | $0.00 | 0% | 3.34x |
|
ADMA
ADMA Biologics
|
$19.80 | $25.27 | $4.7B | 24.15x | $0.00 | 0% | 11.28x |
|
EYPT
EyePoint Pharmaceuticals
|
$6.23 | $33.00 | $428.2M | -- | $0.00 | 0% | 8.10x |
|
OCGN
Ocugen
|
$0.60 | $6.75 | $176.6M | -- | $0.00 | 0% | 40.40x |
|
PTCT
PTC Therapeutics
|
$57.14 | $64.93 | $4.5B | -- | $0.00 | 0% | 5.44x |
|
TGTX
TG Therapeutics
|
$42.99 | $42.83 | $6.8B | 307.07x | $0.00 | 0% | 20.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | 0.335 | -- | 3.71x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
EYPT
EyePoint Pharmaceuticals
|
-- | -2.597 | -- | 7.57x |
|
OCGN
Ocugen
|
49.18% | 4.395 | 12.22% | 2.71x |
|
PTCT
PTC Therapeutics
|
186.52% | -0.744 | 67.49% | 2.23x |
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EDIT
Editas Medicine
|
-- | -$34.4M | -100% | -100% | -112.28% | -$51.3M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
EYPT
EyePoint Pharmaceuticals
|
$10.8M | -$45.2M | -50.34% | -50.34% | -356.36% | -$36.2M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
PTCT
PTC Therapeutics
|
$196.9M | -$15.9M | -382.54% | -- | -25.16% | -$36.5M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Editas Medicine vs. Competitors
-
Which has Higher Returns EDIT or ADMA?
ADMA Biologics has a net margin of -148.33% compared to Editas Medicine's net margin of 95.19%. Editas Medicine's return on equity of -100% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About EDIT or ADMA?
Editas Medicine has a consensus price target of $3.75, signalling upside risk potential of 186.26%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 27.64%. Given that Editas Medicine has higher upside potential than ADMA Biologics, analysts believe Editas Medicine is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 ADMAADMA Biologics4 0 0 -
Is EDIT or ADMA More Risky?
Editas Medicine has a beta of 1.876, which suggesting that the stock is 87.581% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock EDIT or ADMA?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or ADMA?
Editas Medicine quarterly revenues are $30.6M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Editas Medicine's net income of -$45.4M is lower than ADMA Biologics's net income of $111.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 24.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.34x versus 11.28x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.34x -- $30.6M -$45.4M ADMAADMA Biologics11.28x 24.15x $117.5M $111.9M
-
Which has Higher Returns EDIT or EYPT?
EyePoint Pharmaceuticals has a net margin of -148.33% compared to Editas Medicine's net margin of -357.26%. Editas Medicine's return on equity of -100% beat EyePoint Pharmaceuticals's return on equity of -50.34%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M EYPTEyePoint Pharmaceuticals92.96% -$0.64 $336.5M -
What do Analysts Say About EDIT or EYPT?
Editas Medicine has a consensus price target of $3.75, signalling upside risk potential of 186.26%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 429.7%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 EYPTEyePoint Pharmaceuticals9 0 0 -
Is EDIT or EYPT More Risky?
Editas Medicine has a beta of 1.876, which suggesting that the stock is 87.581% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.
-
Which is a Better Dividend Stock EDIT or EYPT?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or EYPT?
Editas Medicine quarterly revenues are $30.6M, which are larger than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Editas Medicine's net income of -$45.4M is lower than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Editas Medicine's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.34x versus 8.10x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.34x -- $30.6M -$45.4M EYPTEyePoint Pharmaceuticals8.10x -- $11.6M -$41.4M
-
Which has Higher Returns EDIT or OCGN?
Ocugen has a net margin of -148.33% compared to Editas Medicine's net margin of -1816.75%. Editas Medicine's return on equity of -100% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About EDIT or OCGN?
Editas Medicine has a consensus price target of $3.75, signalling upside risk potential of 186.26%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1016.44%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 OCGNOcugen2 0 0 -
Is EDIT or OCGN More Risky?
Editas Medicine has a beta of 1.876, which suggesting that the stock is 87.581% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.
-
Which is a Better Dividend Stock EDIT or OCGN?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or OCGN?
Editas Medicine quarterly revenues are $30.6M, which are larger than Ocugen quarterly revenues of $764K. Editas Medicine's net income of -$45.4M is lower than Ocugen's net income of -$13.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.34x versus 40.40x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.34x -- $30.6M -$45.4M OCGNOcugen40.40x -- $764K -$13.9M
-
Which has Higher Returns EDIT or PTCT?
PTC Therapeutics has a net margin of -148.33% compared to Editas Medicine's net margin of -30.91%. Editas Medicine's return on equity of -100% beat PTC Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M PTCTPTC Therapeutics92.36% -$0.85 $1.3B -
What do Analysts Say About EDIT or PTCT?
Editas Medicine has a consensus price target of $3.75, signalling upside risk potential of 186.26%. On the other hand PTC Therapeutics has an analysts' consensus of $64.93 which suggests that it could grow by 13.63%. Given that Editas Medicine has higher upside potential than PTC Therapeutics, analysts believe Editas Medicine is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 PTCTPTC Therapeutics6 4 1 -
Is EDIT or PTCT More Risky?
Editas Medicine has a beta of 1.876, which suggesting that the stock is 87.581% more volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.
-
Which is a Better Dividend Stock EDIT or PTCT?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or PTCT?
Editas Medicine quarterly revenues are $30.6M, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Editas Medicine's net income of -$45.4M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.34x versus 5.44x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.34x -- $30.6M -$45.4M PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M
-
Which has Higher Returns EDIT or TGTX?
TG Therapeutics has a net margin of -148.33% compared to Editas Medicine's net margin of 21.57%. Editas Medicine's return on equity of -100% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital EDITEditas Medicine-- -$0.55 $134.3M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About EDIT or TGTX?
Editas Medicine has a consensus price target of $3.75, signalling upside risk potential of 186.26%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could fall by -0.36%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings EDITEditas Medicine4 9 0 TGTXTG Therapeutics5 0 0 -
Is EDIT or TGTX More Risky?
Editas Medicine has a beta of 1.876, which suggesting that the stock is 87.581% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.
-
Which is a Better Dividend Stock EDIT or TGTX?
Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EDIT or TGTX?
Editas Medicine quarterly revenues are $30.6M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Editas Medicine's net income of -$45.4M is lower than TG Therapeutics's net income of $23.3M. Notably, Editas Medicine's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 307.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 3.34x versus 20.47x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EDITEditas Medicine3.34x -- $30.6M -$45.4M TGTXTG Therapeutics20.47x 307.07x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
